Neurodegenerative diseases
Conditions
Interventions
AD, Alzheimer’s disease
PD, Parkinson’s disease
MSA, Multiple system atrophy
PSP, Progressive supranuclear paralysis
CBD, Corticobasal degeneration
DLB, Dementia with Lewy bodies
FTD, Frontotemporal dementia:None
Sponsors
Shaanxi Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) At least any of AD, PD, MSA, PSP, CBD, DLB, and FTD; 2) PD needs to meet the 2015 International Parkinson's and Movement Disorder Society (MDS) clinical diagnostic criteria (Postuma et al., 2015); 3) AD needs to meet the diagnostic criteria for dementia due to AD in the latest diagnostic criteria for Alzheimer's disease in United States in 2011 (McKhann et al., 2011); 4) MSA needs to meet the 2022 MDS clinical diagnostic criteria (Gilman et al., 2022), which is divided into neuropathologically established, clinically established, clinically probable, and possible prodromal; 5) PSP needs to meet the clinical diagnostic criteria for MDS in 2017 (Hglinger et al., 2017), which is divided into definite, probable, possible, and suggestive of PSP; 6) CBD needs to meet the 2013 diagnostic criteria for corticobasal degeneration (Armstrong et al., 2013); 7) DLB needs to meet the diagnostic criteria for a probable DLB in the 4th Lewy Body Dementia Consortium Consensus Report in 2017 (McKeith et al., 2017); 8) FTD requires a clinical and pathological diagnosis of FTD consistent with the 2001 Frontotemporal Dementia and Pickel's Disease Working Group (McKhann et al., 2001); 9) Patients voluntarily accept blood, saliva and feces collection when they are admitted to the hospital, and voluntarily undergo necessary laboratory examinations and imaging examinations such as blood, saliva and feces; 10) If the collection of cerebrospinal fluid or other body tissue biological samples is involved, due to its traumatic nature, it must be notified in writing and informed consent, and it can only be collected after the patient's consent, otherwise it will not be collected; 11) Aged 18 to 85 years old; 12) Local permanent residents; 13) Patient agrees to participate in this clinical study and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with any focal brain trauma or encephalitis detected by brain imaging studies (CT or MRI); 2) Have a serious disease that affects their survival, such as malignant tumors or AIDS; 3) Those who have a history of severe mental illness or other illnesses and cannot cooperate in completing the entire investigation; 4) Other medical conditions that negatively affect cognitive status; 5) Patients with secondary parkinsonism caused by drug use, vascular lesions, trauma and other factors; 6) Illiterate, color blind, language barrier or other reasons unable to communicate; 7) Pregnant, lactating women or women who may be pregnant within half a year; 8) Patient refuses to participate in this clinical study and is unable to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease progression;Cognitive function level;Clinical global impression (CGI);Percentage of levodopa responses(%LR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression;Anxiety;Freeze gait;Autonomic function;Disability;Salivation;Sleep;Restless legs syndrome (RLS);REM sleep behavior disorder (RBD); | — |
Countries
China
Contacts
Public ContactLi Rui
Shaanxi Provincial People's Hospital
Outcome results
None listed